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proliferation that contributes to the progressivity of 
RA.1-7
Methotrexate is known to trigger liver 
dysfunction as side effect. Liver function is 
evaluated based on alanine aminotransferase (ALT) 
and/or aspartate aminotransferase (AST)  serum 
titer. Elevation of liver enzyme above the upper 
limit indicates liver dysfunction. Based on study in 
India on 30 patients who were treated with MTX 
for 3 months, there was 25% elevation of AST 
above normal range.8 Study in Israel on 119 patients 
who were treated with MTX showed 43% of RA 
patients have abnormal liver enzyme titer.9 Study 
in Iran on 286 patients who were treated with MTX 
found that 23.7% of patients have experienced liver 
dysfunction.10 Based on the previous studies, factors 
that suspected association with liver dysfuction 
are gender, age, MTX cumulative dose, and MTX 
duration therapy.8-11
There is not any study about proportion of liver 
dysfuction on RA patients who are treated with 
MTX in Indonesia. The purpose of this study is to 
know the proportion of liver dysfunction in patients 
who are treated with MTX, and to analyze the 
association between age, gender, MTX cumulative 
dose, MTX therapy duration with liver dysfunction 
incidence, so that clinicians will be more aware 
with MTX use in patients.
Methods
This study is a descriptive-analytic study with 
cross-sectional method. From the sample 
population, AST and ALT lab results, age, gender, 
MTX cumulative dose, and MTX duration therapy 
were obtained. The study was conducted in RSUPN 
Dr Cipto Mangunkusumo (RSCM) and RSCM 
Kencana, Jakarta for 11 months, from January to 
November 2016. 
Data were obtained from patients’ medical 
records unit RSCM and RSCM Kencana, which 
meet inclusion criteria and opposite of exclusion 
criteria. The inclusion criterias are patients who 
fulfill diagnosis criteria of based on ACR/EULAR 
2010, received MTX therapy for minimum period 
of one month, and patients of RSCM and RSCM 
Kencana. The exclusion criterias are patients who 
have other comorbidities that can cause liver 
dysfunction.
Abstract
Background Rheumatoid arhtirtis (RA) is a chronic 
autoimmune disease that mainly attacks joints. 
It may causes joint deformities which leads to 
lower quality of life of RA patients. RA is treated 
with metothrexate (MTX) which inhibiting disease 
progression. MTX is known for its hepatotoxicity side 
effect, which is described by an elevation of aspartate 
aminotransferase (AST) and/or alanine aminotransferase 
(ALT) beyond the upper normal limit. Factors that may 
enhance hepatotoxicity are gender, age, cummulative 
dose of MTX, and duration therapy of MTX. Prevalence 
of hepatotoxicity caused by MTX therapy in RA patients 
in Indonesia is still unknown. The objective of this 
research is to know the proportion of hepatotoxicity 
and its associations with the factors that may enhance 
hepatotoxicity caused by MTX therapy in RA patients in 
RSCM. 
Method Data about gender, age, cummulative dose 
and duration therapy of MTX are obtained from 115 RA 
patients’ medical records. 
Result Proportion of hepatotoxicity in RA patients 
treated with MTX in RSCM is 42.60%. Gender, age, 
cummulative dose and duration therapy of MTX do not 
significantly enhance hepatotoxicity (p>0.05).
Conclusion In conclusion gender, age, cummulative 
dose and duration therapy of MTX do not have 
association with hepatotoxicity in RA patients treated 
with MTX.
Keywords: Rheumatoid Arthritis, Methotrexate, 
Hepatotoxicity
Introduction
Rheumatoid arthritis (RA) is an inflammatory 
disease which has large impacts on daily activities 
of its sufferers. Inflammation manifests as pain 
that causes joint immobility. American College 
of Rheumatology and European Leauge Against 
Rheumatism (ACR-EULAR) created a tool to help 
diagnose RA in 2010. After the diagnosis is set, 
patient would be treated with Disease Modifying 
Anti Rheumatic Drugs (DMRADs). The target 
of DMARDs therapy is inhibiting joint erosion 
and causing remission. Based on ACR guideline 
on management of RA in year 2015, the first line 
therapy for is methotrexate (MTX). MTX works 
by supressing cytokine release and lymphocyte 
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Data were processed by SPSS software and analyzed with 
inferential statistic. Gender and liver function variables were 
analyzed with Fisher test. Age, MTX cumulative dose, and 
MTX therapy duration variables undergone sample normality 
test with Kolmogorov Smirnov test. If the data distribution 
were normal, unpaired T- test between age, MTX cumulative 
dose, and MTX duration therapy and liver function would 
be conducted. If not normal, the Mann-Whitney test would 
be done. From the Mann-Whitney test, p value showed data 
significance.
Result
From 115 samples who were obtained, all the samples were 
given MTX with minimum dosage of 7.5 mg each week for 
minimum duration of one month. Samples do not have any 
comorbidities that could result in liver dysfunction. Samples 
demographic datas are shown in Table 1.
Table 1. Samples Demographic Data
Variable  Result
Gender, frequency (%)
Men
Women
9 (7.83%)
106 (92.17%)
Age (year) 53.55 (19.98−84.53)*
MTX cumulative dose (mg) 480.00 (25.00−3967.50)*
MTX duration therapy (week) 44.00 (4−226)*
AST titer, frequency (%)
Normal
1−2 times above normal
>2 times above normal
73 (63.48%)
36 (31.30%)
6 (5.22%)
ALT titer, frequency (%)
Normal
1−2 times above normal 
>2 times above normal
75 (65.22%)
34 (29.56%)
6 (5.22%)
Liver dysfunction, frequency (%) 49 (42.60%)
*:not normally distributed data, data presented in median (range)
Association between gender and liver dysfunction
There is no significant difference between proportion of men 
and women (p>0.05) in group with liver dysfunction and 
without.
Table 2. Association between gender and liver dysfunction
Variables Normal LFT Disturbed LFT P value
Women 63 (95.5)
3 (4.5)
43 (87.8)
6 (12.2)
0.167
Men
LFT: Liver Function Test
Association between age and liver dysfunction
There is no significant association between age and liver 
dysfunction incidences (p>0.05). 
Table 3.  Association between age and liver dysfunction
Liver function Result P score
Age
Normal 52.85 (19.98−84.53)*
0.46−0.23
Disturbed 54.78 (23.56−72.75)*
*:not normally distributed data, data presented in median (range)
Association between MTX cumulative dose and liver dysfunction
There is no significant association between MTX cumulative 
dose and liver dysfunction incidences (p>0.05). 
Table 4. Association between MTX cumulative dose and liver 
dysfunction 
Liver function Result P score
MTX
cumulative 
dose
Normal
Disturbed
378.75 (25.00−3337.50)*
0.23−0.115
495.00 (50.00−3967.50)*
*:not normally distributed data, data presented in median (range)
Association between MTX duration therapy and liver dysfunction
There is no significant association between MTX duration 
therapy and liver dysfunction incidences (p>0.05). 
Table 5. Association between MTX duration and liver 
dysfunction
 Liver function Result P score
MTX 
duration 
therapy
Normal 43 (4−226) *
0.519−0.259
Disturbed 44 (5−207) *
*:not normally distributed data, data presented in median (range)
Discussion
Proportion of liver dysfuction in patients who are treated 
with MTX in RSCM and RSCM Kencana is 42.60%. The 
proportion of liver dysfunction in this study is higher than 
study conducted by Sotoudenamesh et al which has proportion 
of liver dysfunction 23.7%.11 However, proportion of liver 
dysfunction in this study is suitable with other studies which 
conducted by Ede et al which stated that proportion of liver 
dysfunction is 53% and Bath et al which stated proportion 
of liver dysfunction is 15−50%. RA patients who are treated 
with chronic MTX experienced elevations in ALT and/or AST 
above the normal upper limit. About 5% of which experienced 
elevation until 2 times the normal range.12 This study result 
has 5.22% samples who experienced AST and/or ALT 2 
times normal range. In the literature review by Conway et al 
liver dysfunction incidence is higher than liver dysfunction 
incidence in this study, AST and/or ALT elevations above 
normal upper limit and those who elevated above two times 
normal range is 48.9% and 16.8% respectively.13
Variations of liver dysfunction proportion in other studies 
might be caused different definitions of liver dysfunction. In 
this study, liver dysfunction is described as ALT and or AST 
abnormal result while treated with MTX. Sotoudenamesh 
et al described liver dysfunction as two abnormal ALT 
and AST results in interval of 2 weeks.10 Kremer et al 
described liver dysfunction based on liver hystology. The 
proportion differences also can be caused by different sample 
characteristics (ethnic and genetic variation).10
The time of laboratory test from last administration of 
MTX can also affect the liver enzyme titer. If the lab test were 
conducted after MTX administration, liver enzyme titer would 
be higher.14
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Folic acid supplementation is known to decrease the 
frequency of liver enzyme elevation.15 MTX hepatotoxicity 
mechanism is still unknown but allegedly result from the same 
mechanism of this drug mechanism of action. MTX causes 
inhibition of DNA and RNA synthesis in liver which result 
in damage and degeneration of liver cell. If the patients were 
given folic acid, DNA and RNA synthesis are not disturbed.14, 
16 
Epidemiologically, RA incidence is two to three times 
higher in women than in men. The reason behind it is still 
unknown but thought to be genetic factor that X linked and 
estrogen factor.14 Studies by Amital et al and Parvin et al 
found women are more fragile to liver enzyme elevations.8,9 
Hoekstra et al study shown women are more prone to MTX 
treatment discontinuation.15 However, in this study, gender 
and liver dysfunctions do not have any significant association. 
This study result is suitable to Sotoudenamesh et al study.10
Age median in this study is 52.8 years (19.98, 84.53) 
in group without liver dysfunction and 54.78 years (23.56, 
72.75) in group with liver dysfuncton. There is no significant 
association between age and liver dysfunction incidence. This 
result is suitable to study by Sotoudenamesh et al, Hoekstra, 
and McKendry which also did not find any association 
between age and liver dysfunction in RA patients who are 
treated with MTX.10,15
Most of MTX would be eleminated from the body through 
kidney, meanwhile kidney function would degenerate as 
the age increased. If MTX titer in body high, the risk of 
hepatotoxicity is even higher. Therefore age is considered as 
risk factor for MTX hepatotoxicity. However, some studies 
showed different result from the theory. Study by Felson in 
496 RA patients and Bologna in 469 RA patients did not find 
association between age, kidney function, and elevation of 
liver enzymes.15 In this study, the researchers do not know 
about  patients’ kidney function.
In this study, there is no significant comparison between 
MTX cumulative dose in group with liver dysfunction and 
without liver dysfunction. MTX cumulative dose median in 
group with liver dysfunction is 495 mg, meanwhile in group 
without liver dysfunction is 378.75 mg. Even though there is 
no significant difference, MTX cumulative dose median in 
group with liver dysfunction is higher than cumulative dose 
median in group without liver dysfunction. In this study, MTX 
cumulative dose is lower than in other previous studies. 
The result of this study is not suitable with studies 
which conducted by Sakthiswary et al and Sotoudenamesh 
et al which were acquired significant difference of MTX 
cumulative dose in group with liver dysfunction and without 
liver dysfunction.10,17  According to the theory, incidences 
of hepatotoxicity are associated with increasing MTX dose. 
However, in various studies by West et al and Lanse et al 
also did not find any increasing risk of hepatotoxicity with 
increasing of MTX dose.18
Study by Bath et al showed significant association between 
MTX cumulative dose and liver dysfunction in RA patients 
treated with MTX once a day or every two days. However, in 
RA patients treated with MTX once a week, there is a weak 
association between MTX cumulative dose and hepatotoxicity. 
Liver dysfunction incidence is more associated with time 
interval between two MTX administrations than MTX 
cumulative dose. When the drug is administrated in one week 
interval, MTX titer in the body is not high enough to cause 
hepatotoxicity.18 In this study, RA patients are treated with 
MTX weekly. No significant difference in MTX cumulative 
dose and liver dysfunction could be caused by time interval 
between two administrations. Studies by Parvin et al and Rau 
et al stated that liver enzymes elevations were transient and 
will normalized after decreasing of MTX dose, giving of  folic 
acid, or even without changes in MTX dose. 8,19
No significant difference between MTX cumulative 
dose and liver dysfunction incidence could be caused by 
MTX cumulative dose which are lower in this study than 
other previous studies. In this study, MTX cumulative dose 
median in group without liver dysfunction is 378.75 mg 
and group with liver dysfunction is 495 mg. Meanwhile in 
Sotoudenamesh et al, MTX cumulative dose mean in group 
without liver dysfuncton is 1707.3 mg with 45.2% of them 
were given MTX more than 1.5 g.10 In the literature review 
by Kremer, hepatotoxicity incidence in RA patients who are 
treated with MTX is low. Hepatotoxicity incidence is higher in 
cancer patients who are treated with higher MTX dose.8
The median MTX duration therapy in group with liver 
dysfunction is 43 weeks and without liver dysfunction is 44 
weeks. In this study, there is no significant association between 
MTX duration therapy and liver dysfunction. This result could 
be caused by short MTX duration therapy. Sotoudenamesh et 
al studies found significant association between MTX duration 
therapy and liver dysfunction. In  Sotoudenamesh et al study, 
MTX duration therapy in group with liver dysfunction reached 
59.6±42.3 months.10
MTX duration therapy is associated with MTX cumulative 
dose. However, hepatotoxicity is more associated with time 
interval between two drug administrations than the MTX 
duration therapy. In study by Rau et al, hepatotoxicity is not 
a significant side effect in weekly low dose MTX therapy. 
Patients are more tolerant with weekly MTX therapy than 
daily MTX therapy.
Conclusion
Based on this study, it could be concluded proportion of RA 
patients who have liver dysfunction caused by MTX therapy 
in RSCM is 42.70%. Gender, age, MTX cumulative dose, and 
MTX duration therapy do not have any statistically significant 
association with liver dysfunction. 
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extracellular matrix and autoimmunity.1 Based 
on cutaneous involvement patterns, clinical 
manifestations and laboratory findings, systemic 
sclerosis is classified into 2 types: diffuse 
and limited systemic sclerosis. Cutaneous 
involvement in diffuse systemic sclerosis extend 
up to proximal knees and elbows, face and trunk. 
Raynaud’s phenomenon usually follows cutaneous 
manifestations. Organ involvement such as 
musculoskeletal, kidneys, heart and lungs often 
appear. Signs of limited systemic sclerosis are 
known from the mnemonic CREST syndrome, 
consisting of calcinosis, Raynaud’s phenomenon, 
esophageal dysmotility, sclerodactyly and 
telangiectasia.2 
Ten years survival rate of systemic sclerosis 
patient has increased significantly from 53% 
in 1970s to 67% in 1990s.3 However, this rate 
is lower than SLE patients, which is 93%.4 A 
previous study stated that most frequent cause of 
death in systemic sclerosis patients is related to 
heart and lungs involvement.5 Irreversible organ 
involvement following disease progression may 
further complicates the disease, hence the long-
term prognosis of systemic sclerosis depends on 
organ involvement and disease manifestation.
Systemic sclerosis is the third most common 
patients in rheumatology clinic Dr. Hasan 
Sadikin General Hospital, after systemic lupus 
erythematosus (SLE) and rheumatoid arthritis 
(RA).6 Most of them often delayed referral, 
diagnosis, and management of systemic sclerosis 
from primary health care and district hospital 
take place. As a consequences, patients come to 
rheumatology clinic Dr. Hasan Sadikin General 
Hospital Bandung in severe condition with multiple 
organ involvement. Delayed referral corresponds 
with the low education profile of health care 
provider regarding clinical manifestation and 
laboratory findings of systemic sclerosis. As a 
result, a study about clinical manifestations and 
laboratory findings of systemic sclerosis patient is 
needed as an important information to help health 
care providers establish early diagnosis as a way to 
prevent irreversible organ involvement.
Abstract
Background Systemic sclerosis is a chronic progressive 
multisystem autoimmune disease in connective 
tissue, characterized by its heterogeneous clinical 
manifestation. The purpose of this study is to give 
information regarding clinical manifestations and 
laboratory findings of systemic sclerosis patients to 
establish diagnosis of disease.
Methods This study was conducted using descriptive 
quantitative design in September−October 2016. Data 
was collected from medical records of patients visiting 
Rheumatology Clinic Dr. Hasan Sadikin General Hospital 
from 1 July 2015−30 June 2016 using total sampling 
method. The collected data were expected to comprise 
patient’s clinical manifestation and laboratory finding.
Results Most of patients had cutaneous 57 (100.0%) 
and musculoskeletal 40 (70.2%) involvement. Some 
of the disease manifestations were Raynaud’s 
phenomenon 38 (66.7%), fingertip lesion 33 (57.9%), 
stiffness in skin 34 (59.6%), and arthalgia 29 (50.9%). 
Gastrointestinal involvements were present in 29 
(50.9%) patients. Renal involvement were determined 
from urinalysis result showed proteinuria 10 (17.5%) 
and hematuria 8 (14.0%), found in 24 (42.1%) patients, 
while pulmonary and cardiac involvements were found 
in 30 (52.6%) patients, acknowledged from clinical 
symptoms such as dyspnea 12 (21.1%). Identification of 
autoantibodies was found in 12 (21.1%) patients, with 
10 (17.5%) patients had reactive ANA and 3 (3.5%) had 
positive anti-Scl70.
Conclusion Most of systemic sclerosis patients had 
cutaneous involvement. Renal, pulmonary, and cardiac 
involvement were concluded based on laboratory 
findings.
Keywords: 
Systemic sclerosis, clinical manifestation, laboratory 
finding
Introduction
Systemic sclerosis (SSc) is a chronic progressive 
multisystem autoimmune disease in connective 
tissue, characterized by its heterogeneous clinical 
manifestation. Pathophysiologic processes that 
occur on this disease are vascular abnormality, 
fibrosis due to collagen deposits and excessive 
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Methods
This study conducted during September−October 2016 at 
rheumatology clinic Dr. Hasan Sadikin General Hospital 
Bandung. Medical records of patients was analyzed and 
presented descriptively using a retrospective method. Sample 
was selected using total sampling method. Subjects of this 
study were patients diagnosed with systemic sclerosis who 
were treated at rheumatology clinic Dr. Hasan Sadikin General 
Hospital Bandung during July 1, 2015 to June 20, 2016. After 
ethical clearance letter had been issued, clinical manifestations 
and results of supportive examination that the patient took 
were recorded from their medical records. Afterwards, data 
were grouped based on cutaneous, gastrointestinal, renal, 
cardiac and pulmonary involvement. The exclusion criteria of 
the study was patients who have not been completed data on 
their medical records and patients with overlap syndrome or 
mixed connective tissue disease (MCTD).
Results
Total participants who fulfilled inclusion were 57 patients. 
Table 1 showed characteristic of systemic sclerosis patients 
in rheumatology clinic Dr. Hasan Sadikin General Hospital. 
The table showed that most of systemic sclerosis patients 
was female 56 (98.2%) with age range from 31−40 years 19 
(33,3%).
Table 1. Characteristics of SSc patients at rheumatology clinic 
Dr. Hasan Sadikin Bandung General Hospital in July 2015−June 
2016
Characteristics Frequency (n=57) Percentage (%)
Sex
Female
Male
56
1
98.2%
1.8%
Age
<20 years
20-30 years
31-40 years
41-50 years
51-60 years
>60 years
1
9
19
17
5
6
1.8%
15.8%
33.3%
29.8%
8.8%
10.5%
Table 2 showed the distribution of clinical manifestation 
in involved organ on patients with systemic sclerosis at 
rheumatology clinic Dr. Hasan Sadikin General Hospital 
Bandung. The table showed that all 57 subjects are patient with 
cutaneous involvement (100.0%). Raynaud’s phenomenon 
was found in 38 (67.9%) patients.
Table 2. Distribution of clinical manifestations on organs involved 
in SSc patients at rheumatology clinic Dr. Hasan Sadikin General 
Hospital Bandung in July 2015−June 2016
Clinical Manifestation Frequency (n=57) Percentage (%)
Skin
Raynaud’s Phenomenon
Fingertip lesion
Telangiectasia
Calsinosis cutis
Sclerodactyly
Hardened skin
n = 57
38
33
9
21
25
25
100.0%
66.7%
57.9%
15.8%
36.8%
43.9%
43.9%
Clinical Manifestation Frequency (n=57) Percentage (%)
Skin stiffness
Painful skin
Itchy skin
Mask-face
Fish mouth
Salt and pepper appearance
34
26
16
8
22
19
59.6%
45.6%
28.1%
14.0%
38.6%
33.3%
Gastrointestinal
Nausea
Difficulty in swallowing
Epigastric pain
Diarrhea
n = 29
14
13
6
4
50.9%
24.6%
22.8%
10.5%
7.0%
Musculoskeletal
Swelling fingers
Arthalgia
Myalgia
Joint stiffness
Muscle contracture
Knee pain
Back pain
n = 40
14
29
13
10
2
6
4
70.2%
24.6%
50.9%
22.8%
17.5%
3.5%
10.5%
7.0%
Renal n=24 42.1%
Pulmonary and cardiac n=30 52.6%
 
Table 3 showed multiple of organ involvements in systemic 
sclerosis patient. Most patients (40.4%) had combination of 
skin, musculoskeletal, and gastrointestinal organ 
Table 3. Distribution of multiple organ involvements in SSc 
patients at rheumatology clinic Dr. Hasan Sadikin General 
Hospital Bandung in July 2015−June 2016
Multiple Organ Involvements Frequency (n=57) Percentage (%)
Skin only 13 22.8%
Skin and musculoskeletal 16 28.1%
Skin and gastrointestinal 5 8.8%
Skin, musculoskeletal, and 
gastrointestinal
23 40.4%
  
Table 4 showed the distribution of constitutional symptoms 
which appeared on systemic sclerosis patients at rheumatology 
clinic Dr. Hasan Sadikin General Hospital. The table showed 
that the most frequent constitutional symptoms experienced 
by patients were easy fatigability 12 (21.1%) and weakness 
11 (19.3%).
Table 4. Distribution of constitutional symptoms in SSc patients 
at rheumatology clinic Dr. Hasan Sadikin General Hospital 
Bandung in July 2015−June 2016
Constitutional Symptom Frequency (n=57) Percentage (%)
Easily fatigue 12 21.1%
Weakness 11 19.3%
Hair fall 6 10.5%
Epistaxis 4 7.0%
Weight loss 8 14.0%
 
Renal, cardiac and pulmonary involvement in patients with 
systemic sclerosis can be assessed from clinical manifestations 
and/or supporting examination. Examinations which usually 
carried out were routine urinalysis, serum creatinine, plain 
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chest x-ray, chest CT scan, spirometry and echocardiography. 
Table 5 showed the distribution of clinical manifestations and 
laboratory findings of systemic sclerosis patients with renal, 
cardiac and pulmonary involvement at Dr. Hasan Sadikin 
General Hospital.
Tabel 5. Distribution of clinical manifestations and laboratory 
findings on renal, cardiac, and pulmonary involvement in SSc 
patients at rheumatology clinic Dr. Hasan Sadikin General 
Hospital Bandung in July 2015−June 2016
Organ Involvement Frequency (n=57) Percentage (%)
Renal Involvement
Clinical manifestation
Dysuria
Oligouria
Laboratory findings
Urinalysis
Proteinuria
Hematuria
Bakteriuria
Increased creatinine serum
n=24
6
2
10
8
3
4
42.1%
10,5%
3,5%
17,5%
14,0%
5,3%
7,0%
Pulmonary and Cardiac Involvement 
Clinical manifestation
Dyspnea
Dyspnea with edema in lower 
extremities
Dyspnea with cough
Cough
Palpitation
Laboratory findings
Plain chest x-ray
Cardiomegaly
Cardiomegaly without pulmonary 
edema
Suspected ILD
Idiopathic pulmonary fibrosis
CT Scan
ILD appearance
Spirometry
Mild restrictive
Moderate restrictive
Echocardiography
Pulmonary hypertension 
Diastolic dysfunction
n=30
12
2
7
5
2
2
5
2
1
3
2
4
2
1
52,6%
21,1%
3,5%
12,3%
8,8%
3,5%
3,5%
8,8%
3,5%
1,8%
5,3%
3,5%
7,0%
3,5%
1,8%
 
Table 6 showed the distribution of autoantibody test result 
on systemic sclerosis patients at Dr. Hasan Sadikin General 
Hospital Bandung. The tests included antinuclear antibody 
(ANA) and anti-Scl70.
Table 6. Distribution of autoantibody test in SSc patients at 
rheumatology clinic Dr. Hasan Sadikin General Hospital Bandung 
in July 2015−June 2016
Autoantibody Frequency (n=57) Percentage (%)
Autoantibody test
ANA
Reactive
Speckled pattern
Nuclear pattern
Homogenous type
Not-specified
Non-reactive
Anti-Scl70
Positive
n=12
10
2
3
3
2
2
3
21.1%
17.5%
3.5%
5.3%
5.3%
3.5%
3.5%
5.3%
N/A 45 78.9%
Discussions
It was obtained from this study that most patients with 
systemic sclerosis were female 56 (98.2%) with age range 
from 31-40 years 19 (33.3%). This result corresponded with 
previous study conducted by Pagalavan dan Ong in Malaysia, 
where most systemic sclerosis patients were 31−40 years old 
female.7
All systemic sclerosis patients showed cutaneous 
involvement as disease manifestation. This result suited 
to previous study which stated that even though clinical 
manifestations in systemic sclerosis were heterogeneous, 
most patients had cutaneous involvement.8 Systemic 
sclerosis patients which showed clinical manifestation and 
positive laboratory findings on organs without any cutaneous 
involvement were called systemic sclerosis sine scleroderma 
(ssSSc). On a study conducted by Marangoni, et al., in Brazil, 
it was found that among 947 systemic sclerosis patients, there 
were only 79 (8.3%) patients with ssSSc.9
Based on Le Roy vascular hypothesis, dysfunctional blood 
vessel was an initial pathophysiologic process in systemic 
sclerosis marked by Raynaud’s phenomenon.10 The result of 
this study revealed that the most frequent clinical manifestation 
found on skin was Raynaud’s phenomenon (66.7%). This 
result corresponded with a previous study conducted by 
Pagalavan and Ong in Malaysia, where 38 (83.6%) patients 
with systemic sclerosis experienced Raynaud’s phenomenon.7 
Hanitsch in Germany published a higher rate; 1160 (96.7%) 
patients experienced Raynaud’s phenomenon.11
This study revealed that 9 (15.8%) patients experienced 
telangiectasia and 21 (36.8%) patients experienced cutaneous 
calcinosis. This result was different with the study by 
Pagalavan and Ong in Malaysia, where 28 (45.9%) patients 
experienced telangiectasia and 7 (11.5%) patients experienced 
calcinosis cutis.7 The result might be affected by the type of 
systemic sclerosis experienced by patients, calcinosis cutis 
was more frequently found in limited systemic sclerosis.12
Musculoskeletal involvement as the main cause of 
disability was frequently found on systemic sclerosis.13  From 
the study result, it was revealed that 40 (70.2%) systemic 
sclerosis patients had a musculoskeletal involvement. The 
most frequently found manifestation was arthalgia 29 (50.9 
%). This result was suitable with the previous literature 
which stated that the most common clinical manifestation 
on musculoskeletal involvement was arthalgia.14 This result 
corresponded with the study by Pagalavan and Ong in Malaysia 
which reported that arthalgia/arthritis were frequently found 
(49.2%).7
There were 29 (50.9%) systemic sclerosis patients in 
this study with gastrointestinal involvement. The most 
manifestation which frequently found was difficulty in 
swallowing 13 (22.8%). This result corresponded with 
previous study which stated that gastroesophageal reflux 
and dysphagia were the frequent manifestations of systemic 
sclerosis on patients.15 The other common complaint were 
nausea 14 (22.8%). These gastrointestinal manifestations 
were one factor which might cause malnutrition on systemic 
sclerosis patients. Baron, et al reported 18% patients were at 
risk for malnutrition.16
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On this study, the most frequent constitutional symptoms 
reported by systemic sclerosis patients were fatigue (21.1%) 
and weakness (19.3%). This result suited to previous study 
by Sandusky, et al., in USA which stated that 76% subjects 
experienced fatigue, while 61% of those patients stated that 
this was one of the most physically and socially disturbing 
symptoms.17
Renal involvement on systemic sclerosis patients can 
be assessed from clinical features or from supporting 
examination. On this study, there were 24 (42.1%) patients 
with renal involvement; 8 (14.0%) patients with clinical 
symptoms such as dysuria (10.5%) and oliguria (3.5%), while 
the rest of them had abnormal supporting examination test 
result. The supporting examinations conducted were routine 
urinalysis and serum creatinine level. Abnormalities found on 
patients from those test were proteinuria (17.5%), hematuria 
(14.0%) and bacteriuria (5.3%). Albuminuria could be used as 
vasculopathy marker, which was one of the pathophysiologic 
processes on systemic sclerosis.18 On this study, increasing 
creatinine serum level was found on 4 (7.0%) patients. The 
increasing creatinine serum level did not completely describe 
a renal dysfunction, since renal dysfunction could also occur 
on patients with normal creatinine serum level.18
There were 30 (52.6%) patients on this study showed 
cardiac and pulmonary involvement marked by clinical 
manifestations and supporting examination. On this study, 
there were 12 (21.1%) patients with dyspnea, 2 (3.5%) 
patients with dyspnea and edema on extremities and 7 
(12.3%) patients with dyspnea and cough. Meanwhile, a study 
by Hanitsch in Germany reported 390 (32.5%) patients had 
dyspnea.11 Patients with dyspnea needed further observation 
and screening for pulmonary hypertension. The most frequent 
pulmonary manifestations and the main cause of death on 
60% systemic sclerosis patients were interstitial lung disease 
(ILD) and pulmonary hypertension.19 From plain chest x-ray 
and chest CT scan, respectively there were 2 (3.5%) and 3 
(5.3%) patients with interstitial lung disease, while from 
echocardiography there were 2 (3.5%) patients with pulmonary 
hypertension. Systolic and diastolic dysfunction are early 
signs of heart problems on patients with systemic sclerosis.20 
On this study, there were 1 (1.8%) patients presented with 
diastolic dysfunction from echocardiography.
One of the pathophysiologic process occur on systemic 
sclerosis is the synthesis of autoantibody. The number and 
level of this autoantibody fluctuates depending on the disease 
activity, hence it could be used as diagnostic markers and 
determine prognosis of systemic sclerosis.2 There were 10 
(17.5%) patients on this study had positive ANA (antinuclear 
antibody) test result while 3 (5.3%) patients with positive 
anti-Scl70. This result was different from Pagalavan and Ong 
in Malaysia who stated that there were 51 (83.6%) patients 
with positive ANA and 21 (34.4%) patients with positive 
anti-Scl70 test result. This difference because not all patients 
who were treated at rheumatology clinic Dr. Hasan Sadikin 
General Hospital had autoantibody tests.7
Conclusion
From 57 sample, it could be concluded that most systemic 
sclerosis patients had cutaneous involvement, renal, 
pulmonary, and cardiac involvement based on laboratory 
findings.
This study was a retrospective study that evaluated 
history taking and supporting examination test result on 
medical records. Most of the medical records had not been on 
computerized system, hence there could still be a possibility 
that there were mistakes in interpreting the writings on the 
medical records. On the other hand, not all patients took 
autoantibody test hence their records were not reported.
Recommendation from this study is demographic data on 
medical records could be completed. The medical records 
should also comprise the recordings of all examination the 
patient took to help clinician establish the diagnosis of the 
patient.
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autoimmune connective tissue disease that involving 
many organs. The etiology of this disease is still 
not well known.1-3 Lung is common organ involved 
in systemic sclerosis patients, such as Interstitial 
Lung Disease (ILD) and pulmonary arterial 
hypertension.4 Systemic Sclerosis patients suffered 
with ILD tend to has lower quality of life compared 
to healthy person.5 European Scleroderma Trials 
and Research (EUSTAR) group reported ILD was a 
major cause of death in systemic sclerosis. Data of 
5800 systemic sclerosis patients showed as much as 
35% deaths caused by pulmonary fibrosis, 26% by 
pulmonary arterial hypertension and 4% by kidney 
disorder.6
ILD is difficult to diagnose, especially in 
developing country, due to unavailability of High 
Resolution Computed Tomography (HRCT) 
scanning which is the gold standard for diagnosing 
ILD.4,7,8 Moreover, it is not affordable for the 
most patients. Other pulmonary function tests 
are more commonly used as initial screening of 
ILD in systemic sclerosis patients in our center.4,7 
Those PFT instruments consist of test for diffusing 
capacity of the lung for carbon monoxide (DLCO), 
spirometry to define forced vital capacity (FVC), 
etc. The pulmonary function tests (PFT) play as 
key role to determine the severity of pulmonary 
complication in SSc patients. FVC is one of the 
common test which use to determine the severity of 
restrictive abnormality in ILD.8
T-cells trigger fibroblasts activation which 
causing fibrosis process in systemic sclerosis 
patients. Activated CD4 T-cells will express CD40 
ligand (CD40L/CD154) that binds to CD40 on 
the surface of the B-cells. T cells will produce 
cytokines and stimulate fibroblast to start fibrosis 
cascade as the main pathogenesis of systemic 
sclerosis.9 CD40L is suggested playing role in 
fibrosis cascade. CD40L can be cleaved from the 
cell surface, releasing a soluble CD40L (sCD40L) 
which is biologically active.10,11 Allanore, et 
al reported  an increase of plasma sCDL40 
associated with vascular complication in systemic 
sclerosis patients. Instead, other studies reported 
controversially role of CD40-CD40L bond in 
pulmonary fibrosis.11,12
Aim of this study is to analyze the correlation 
of sCD40L level with FVC value in restrictive lung 
Abstract
Background: Interstitial Lung Disease (ILD) is one of 
the major cause of morbidity and mortality in Systemic 
Sclerosis (SSc). The gold standard to diagnose ILD is 
using High Resolution Computed Tomography (HRCT) 
scan. HRCT scan need a lot of cost and not always 
available, so another diagnosing test is needed as an 
alternative modality to diagnose ILD. ILD is a restrictive 
lung disease caused by lung fibrosis which is proved 
by the decrease of Forced Vital Capacity (FVC) in 
spirometry, and followed by the increase of soluble 
CD40L (sCD40L) level in plasma. This sCD40L may 
become a potential biomarker to evaluate lung fibrosis 
in SSc patients. The aim of this study is to analyze the 
correlation of sCD40L levels with FVC score  in SSc 
patients with restrictive lung disease.
Method: This cross sectional study was enrolled by the 
SSc patient who has restrictive lung disease based on 
spirometry test, at Rheumatology outpatient clinic dr. 
Hasan Sadikin Hospital from May 2015 to May 2016. All 
subject took underwent history, physical examination, 
spirometry and blood test for sCD40L. Data were 
analyzed using Pearson correlation.
Result: There were 38 subjects involved in this study, 
dominated bywoman (92.1%) with mean age 41(±11) 
years. Subjects consist of 22(57,9%) with limited SSc, 
16(42,1%) with diffuse SSc patients and 33 subjects 
treated with DMARD. Mean sCD40L serum in this study 
was 6.690,3(±2.377,3) pg/mL, with no statistical 
difference between limited and diffuse type (p=0.154). 
Mean FVC score in this study was 58.2(±10,8). There 
was no significant correlation between sCD40L serum 
with FVC (r=0.058; p=0.366). There was weak 
correlation on DMARD naïve subject between sCD40L 
serum and FVC (r=0.058; p=0.366) but statistically 
insignificant. There was no significant correlation 
between sCD40L serum with mRSS (r=0,066; 
p=0,346).
Conclusion: This study founds no correlation between 
sCD40L with FVC in SSc at dr. Hasan Sadikin Hospital.
Keyword: sCD40L, Forced Vital Capacity, Restrictive 
Lung Disease, Systemic Sclerosis 
Introduction
Systemic Sclerosis (SSc) is a chronic progressive 
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disease of systemic sclerosis patients. 
Method
This cohort retrospective study enrolled the systemic sclerosis 
patients who had restrictive lung disease based on spirometry 
test. Data were collected from outpatient subjects at clinic 
rheumatology, Hasan Sadikin General Hospital from May 
2015 to May 2016. The inclusion criteria were patients who 
diagnosed with systemic sclerosis based on ACR/EULAR 
2013 criteria with restrictive lung disorders and willing to 
participate in this study, includes carried out blood test and 
spirometry examination. Exclusion criteria were patients who 
diagnosed with other autoimmune diseases and/or diagnosed 
with restrictive lung disease other than ILD through history, 
physical examination and history from previous medical 
records.
This study used two step of data collection. Initial step 
was screening to get subjects who meet the inclusion and 
exclusion criteria. The next step was venous blood sampling 
to determine the sCD40L level followed by spirometri test to 
evaluate FVC value. Then data was analyzed with Pearson 
correlation test.
Result
We included 38 patients in this study. Characteristics of the 
subject are shown at table 1. 
Table 1. Characteristics of Subjects
Characteristics
All Subjects
n=38
Limited Type
n=22 (57.9%)
Diffuse Type
n=16 (42.1%)
Age (mean ± SD) years 41 ± 11
Sex 
Male (n%) 3 (7.9)
Female (n%) 35 (92.1)
Treatment History
Methotrexate (n%) 33 (86.8)
Steroid (n%) 33 (86.8)
Cyclophosphamide (n%) 2 (5.3)
DMARD-naïve (n%) 5 (13.2)
mRSS (median, range) 17 (4 – 36) 12 (4 – 23) 27 (10 – 36)
FVC (mean ± SD) 58.2 ± 10.8 57,1 ± 12,7 59,6 ± 7,5
sCD40L (mean ± SD) (pg/mL) 6690.3±2377.3 6218,0 ± 2170,7 7339,8 ± 2562,5
The median of modified Rodnan Skin Score (mRSS) is 17 
and has range 4 to 36. Mean of FVC by spirometry examination 
was 58.2 + 10.8. The most were 15 (40%) moderate restrictive 
lung patients, 10 (26%) severe restrictive lung patients, 
8 (21%) moderate to severe restrictive lung patients, and 5 
(13%) mild  restrictive lung patients. Mean of sCD40L was 
6690.3±2377.3 pg/mL. There were no statistically different 
of sCD40L level and FVC value between diffuse type and 
limited type systemic sclerosis subjects.
There was five (13.2%) subjects who were for the first time 
diagnosed as systemic sclerosis and had never taken DMARD 
treatment before this study. mRSS score was higher in 
DMARD-naïve patients (p = 0.036, Mann-Whitney) sCD40L 
and FVC had no different between DMARD patients and 
DMARD-naïve patients shown in table 2.
Tabel 2. Difference between DMARD and DMARD-naïve patients
Variabel DMARD-naïven=5
DMARD
n=33 p-value
mRSS (median, range) 32 (15 – 36) 14 (4 – 34) 0.036
sCD40L (mean ± SD) 5909.8 ± 783.8 6808.6 ± 2519.5 0.438
FVC (mean ± SD) 58.4 ± 9.1 58.1 ± 11.1 0.958
Bivariate test was used to analyze correlation between 
sCD40L level and FVC value revealed that sCD40L was not 
correlated with FVC (r=0.058, R2 = 0.0034, p=0.366, Pearson 
correlation). Figure 1 show scatter diagram of this study.
Figure 1. Scatter diagram between sCD40L and FVC
There was weak correlation on DMARD naïve subject 
between sCD40L serum and FVC (r=-0.225; p=0.358, Pearson 
correlation) but not significant as shown in table 3.
Tabel 4. Bivariate Analysis between sCD40L and FVC in DMARD 
and DMARD-naïve Patients
Variable Patients
FVC
r p-value
sCD40L
DMARD-naïve -0.225 0.358
DMARD 0.069 0.351
Discussion
Average age of the subjects was 41±11 years, it is in accordance 
with the onset of systemic sclerosis disease which the highest in 
the fourth and fifth decade.13,14 Mean age was smaller compared 
to the research conducted by Allanore et al (50 subjects) 57±11 
years and Komura et al (49 subjects) 51.4±15.6 years but in 
accordance with study on Asian population in Singapore by 
Low et al (200 subjects), namely 46±14.9 years.11,15,16 This 
difference maybe due to race differences in both populations. 
So, age of systemic sclerosis patient in Caucasian population 
is older than in Asian populations.
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Most of the subjects were women (92.1%). These results 
were differed by the proportion of women and men incidence 
in US that reached 3−5:1.1,14,17 But, similar to the result 
obtained by Komura, et al. study in Asia (92%) and Low 
research in Singapore (86%).15,16
Mean FVC value by spirometry was 58.2±10.8%. All 
subject as restrictive lung disorder that may be a pulmonary 
fibrosis. There was no difference in FVC value between limited 
type and diffuse type subjects (p=0.482). Abnormalities of 
pulmonary fibrosis is more common in diffuse type since it is 
a rapidly progressing disorder that affects a large area of the 
skin and compromises one or more internal organs including 
lung. Expression of antinuclear antibody is more dominant 
in diffuse type SSc compared to the limited type.1 FVC 
examination can be used as an initial screening test but the 
incidence of pulmonary fibrosis may not be used as the gold 
standard to diagnosis pulmonary fibrosis.
Mean of sCD40L levels in our study were 6690.3±2377.3 
pg/mL. This is higher when compared with control values  in 
Allanore, et al study (median sCD40L 79 (50−118) pg/mL) 
and Salibi, et al. study (mean sCD40L 717 pg/mL). sCD40L 
levels in our study is also higher than sCD40L level in systemic 
sclerosis patients in Allanore, et al. study with a median 
sCD40L 495 (10−2690) pg/mL and Salibi, et al study with 
a mean sCD40L 1564 pg/mL.11,18 This difference happened 
due to the difference subjects involved in Allanore, et al study 
used all systemic sclerosis patients with or without pulmonary 
complication, while in the Salibi, et al study, the subjects 
were included the lung fibrosis subjects with any underlying 
disease. Whereas the subjects in our study were the systemic 
sclerosis patients with restrictive lung disorders. CD40L 
is believed to play role in the fibrosis cascade of systemic 
sclerosis patients. CD40-CD40L bond between T-cells and 
B-cells trigger proliferation and differentiation of B-cells 
into plasma cells and forms a bond autoantibody.19,20 CD40-
CD40L activates the proliferation of fibroblasts, produces 
pro-inflammatory cytokines, and begins fibrosis process.21,22 
Komura and Fukasawa reported the increase of plasma CD40 
protein due to CD40 expression on fibroblasts surface in 
systemic sclerosis patients.15,21 CD40L can be cleaved from 
cell surface and dissolved as a soluble CD40L on plasma that 
biologically active.10,23
From our study, we found no statistically correlation 
between sCD40L level and FVC (r=0.058, R2=0.0034, 
p=0.366). This is consistent with Allanore, et al study that 
reported lack correlation between sCD40L levels with 
pulmonary fibrosis and carbon monoxide diffusing capacity 
(DLCO).11 Other study by Salibi, et al reported a significantly 
increasing of sCD40L levels in pulmonary fibrosis patients 
when compared to the healthy population (p < 0.05).18 Salibi, 
et al also reported a correlation sCD40L level with FVC 
(R2=0.16, r=0.4) but not significantly related (p=0.16).12
There are some differences between our study and the 
study conducted by Allanore, et al or Salibi, et al. This study 
included 38 subjects while Allanore, et al study followed by 
50 subjects and Salibi et al study followed by 13 subjects. This 
study uses retrospective cohort while the two other studies 
using cross sectional method. This research together with 
Salibi, et al analyzed the correlation of sCD40L levels with the 
value of FVC, while Allanore, et al analyzed the association of 
sCD40L levels with the incidence of pulmonary fibrosis and 
DLCO. 
Other difference is our study and Allanore, et al study 
used systemic sclerosis patients, while Salibi, et al. research 
used all subjects with pulmonary fibrosis. Study conducted 
by Allanore, et al only involve systemic sclerosis patients 
who have not received immunosuppressive therapy, while 
in our study, only five subjects who have not received 
immunosuppressive therapy and the remaining subjects have 
been treated with methotrexate.
Different level of sCD40L may be affected by several 
conditions in our subject settings. First, 83.8% subject has been 
treated with DMARD (methotrexate, cyclophosphamide). 
Methotrexate could interfere activation of T-cell that might 
affect the level of sCD40L.24 Second, we measured sCD40L 
to represent the activity of CD40L, because sCD40L has the 
CD40L biologic activity. However, there were not any data 
about the equivalent of sCD40L level on serum and CD40L 
level on T-cell. Third, many factors could interfere the result 
of FVC measurement such as age, sex, weight, height, chest 
abnormality. Fourth, disease activity shown by sCD40L level 
might fluctuate rapidly while lung damage shown by FVC 
level might be change in a slow progression.
Conclusion
Our study showed increased plasma soluble CD40 ligand 
concentrations in restrictive lung disease of systemic sclerosis 
patients. Our result found no significant correlation between 
sCD40L with FVC in SSc at dr. Hasan Sadikin General 
Hospital.
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Abstract
Background: WHO-ILAR COPCORD Program is a 
program that aimed to obtain data on joints pain and 
musculoskeletal diseases in developing countries, 
one aspect which has not been studied is the ability 
of COPCORD questionnaire as a screening tool 
which standardized for  screening  joint pain and 
musculoskeletal diseases. Objective of this study is to 
assess the validity of modified COPCORD questionnaire 
Indonesian version in screening joint pain and 
musculoskeletal disease compared to examination by 
rheumatologists.
Methods: The initial phase of the research is 
determining essential points, translation to Indonesian, 
and back translation. The second stage is testing 
questionnaires in communities which 100 respondents 
involved. Dependent variable is the diagnosis of 
rheumatic diseases and independent variables are pain 
in less and more than 7 days, high degree pain in less 
and more than 7 days, history of NSAIDs/Steroids/
DMARDs use, and disabilities. Validation test was 
assessed by calculating the sensitivity, specificity, PPV, 
NPV, LR+, and ROC curve. Bivariate analysis using Chi 
Square analysis, and multivariate analysis using logistic 
regression.
Results: The sensitivity test results is best obtained on 
the question history of NSAIDs/steroids/DMARDs use 
(100%)  and specificity is best obtained on the question 
about disability (98%). ROC curve analysis which the 
results >85% obtained on the question of pain >7 days 
(90%), high degree pain >7 days (93%), and history of 
NSAIDs/steroids/DMARDs use (92%).  LR+ to diagnose 
rheumatic diseases found in all questions. Chi square 
analysis showed that all questions were significant with 
p <0.05 and odds ratio (OR) obtained most on high 
degree pain more than 7 days (OR: 180.167; 95% CI: 
38.196-849.834). 
Conclusion: The modified COPCORD questionnaire 
Indonesian version has been adapted and can be a good 
tool in the screening of joint pain and musculoskeletal 
diseases compared to examination by rheumatologists.
Keyword: Validation, Questionnaire, COPCORD
Introduction
Joint pain and musculoskeletal disease is the most 
common cause of morbidity in general population. 
Even rheumatic diseases not increase mortality 
but it can lead to disabilities and low quality of 
life and productivity.1 On the other hand the need 
of data on the magnitude of the problem and the 
effects of joint and musculoskeletal diseases is very 
important, especially in developing countries such 
as Indonesia. Based on these data we can see the 
effect of the disease and provide recommendation 
and intervention plan both in terms of detection and 
therapy.2
In the 1981 the International League against 
Rheumatism (ILAR) and the World Health 
Organization (WHO) jointly launched the WHO-
ILAR Community Oriented Program for the Control 
of Rheumatic Diseases (COPCORD) to obtain 
data on the joints and musculoskeletal diseases in 
developing countries. COPCORD is a low cost 
program which requires minimal infrastructure 
by relying on existing resources. Using the same 
and validated method, COPCORD Phase 1 ( out of 
3 phase) has been succeeded to collect data from 
Australia,3 Bangladesh,4 Brazil,5 Chile,5 China,6 
Cuba,7 Egypt,8 Guatemala,9 India,10 Indonesia,11 
Iran,12 Kuwait,13 Malaysia,14 Mexico,5, 15 Pakistan,16 
Philippines,17 Thailand,18 Taiwan,19 Tunisia20 and 
Vietnam.10, 21-23
One aspect of COPCORD which has not been 
studied is the ability COPCORD questionnaire as 
a screening tool that is standardized in rheumatic 
diseases. For population who has limited health 
facility level or limited time and resources, 
this questionnaire would be more suited to be 
applied in a broad population. The consideration 
of COPCORD as a standardized tool, requires 
validation of certain aspects like diagnostic tests, 
especially when compared to complete examination 
conducted by rheumatologist.24, 25 In the other hand, 
the adaptation and translation into Indonesian 
questionnaire also have consequences in language 
and cultural adaptation that may be different from 
the original.26 Based on this fact, it is necessary 
to validate a modified COPCORD questionnaire 
Indonesian version for screening of joint pain and 
musculoskeletal diseases in Malang.
The aim of this study is to assess the validity 
of modified COPCORD questionnaire Indonesian 
version, for screening joint pain and musculoskeletal 
disease in the population compare to examination 
done by rheumatologist.
